医学
内科学
减肥
2型糖尿病
糖化血红素
胃肠病学
糖尿病
体质指数
内分泌学
脂肪变性
非酒精性脂肪肝
脂肪肝
丙氨酸转氨酶
2型糖尿病
肝病
肝硬化
胰岛素抵抗
慢性肝病
血红蛋白
丙氨酸转氨酶
纤维化
作者
Savvoula Savvidou,Elektra Augousti-Varela,Aikaterini Damianakou,Miltiadis Chalkias,Ioannis Stergiou
标识
DOI:10.1177/15578518251409025
摘要
Background: Semaglutide is currently being investigated for its effectiveness in metabolic dysfunction-associated steatotic liver disease (MASLD), irrespective of type 2 diabetes mellitus (T2DM) presence, even though its action on hepatic fibrosis is still debated. The aim of this study was to examine the effect of semaglutide on hepatic parameters in patients with both T2DM and MASLD in real-world clinical practice, and to further assess the significance of weight loss during treatment. Methods: In consecutive patients with T2DM and MASLD, hepatic biochemistry and Fibrosis-4 (FIB-4) score were recorded. In participants with high FIB-4, elastographic liver stiffness measurements (LSM) and controlled attenuation parameter (CAP) were acquired with FibroScan® before and after treatment with semaglutide. For within-group comparisons, Wilcoxon signed ranked test for related samples was performed, while the role of weight loss was further investigated. Results: A total of 111 patients were included: 31 males (27.9%), with a mean age 56.4 ± 9.7 years old, body mass index 32.7 ± 6.3 kg/m 2 , and median glycated hemoglobin (HbA1c) 5.8% (interquartile range [IQR]: 5.6–6.2). Semaglutide (0.5–2.4 mg/week) was administered subcutaneously for a median of 12 months (IQR: 6.6–17). Thirty-three patients (29.7%) had aspartate aminotransferase and/or alanine aminotransferase above normal, and 35 (31.5%) high FIB-4 score. Apart from an overall drop in HbA1c of 5.6% (IQR: 1.6–8.6) and weight loss of 10% (IQR: 3.2–19.6), statistically significant reductions were recorded in all liver enzymes and elastographic parameters ( p < 0.001). In multiple regression analysis, weight loss was found to independently predict improvements in aminotransferases and measured CAP ( p < 0.001), irrespective of treatment duration and baseline FIB-4. Conclusion: In this cohort of T2DM/MASLD patients with baseline optimal glycemic control, semaglutide-induced weight loss led to significant improvements of all hepatic parameters (biochemistry, liver stiffness, and steatosis assessed with CAP), even in MASLD patients with baseline liver enzymes within normal. This study supports the advantages of semaglutide administration in concomitant T2DM and MASLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI